about
Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncologyCapecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.Targeted agents: how can we improve the outcome in biliary tract cancer?Biliary tract carcinomas: from chemotherapy to targeted therapy.Potentially resectable metastatic colorectal cancer: an individualized approach to conversion therapy.Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
P50
Q28085398-CC610F59-D51E-4E9C-8CD5-DAA2D27454CFQ33428348-5CBC1B52-9C0F-4F7B-B2B7-5F0E21B6D6B4Q37584590-4DDD4205-E1B3-42BD-9F39-A46809E81176Q38027255-500D5148-A3B5-4247-BFFA-D8D2DB2FC296Q38225347-2494AFE7-E82F-4446-9A1D-D0481BBDAC05Q38672368-E1F1FC29-6A95-491F-BC67-576188E9637EQ38835601-6F8D5E90-83B7-45EE-AF63-DFF7E17A5161Q40352514-9E44A5AE-F3CA-49D5-AA5C-52A245C9BD87
P50
description
researcher ORCID ID = 0000-0001-6565-0870
@en
wetenschapper
@nl
name
D Marino
@ast
D Marino
@en
D Marino
@nl
type
label
D Marino
@ast
D Marino
@en
D Marino
@nl
prefLabel
D Marino
@ast
D Marino
@en
D Marino
@nl
P31
P496
0000-0001-6565-0870